Orum Therapeutics Announces Presentation of Preclinical Data for ORM-1153
Orum Therapeutics Announces Presentation of Preclinical Data for ORM-1153 at the 2025 American Society of Hematology (ASH) Annual Meeting
BOSTON & DAEJEON, South Korea---Orum Therapeutics, a public biotechnology company pioneering the field of degrader-antibody conjugates (DACs), today announced that preclinical data for ORM-1153, a CD123-targeting DAC with a GSPT1-degrading payload, have been selected for presentation at the upcoming 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6 to 9, 2025, in Orlando, Florida.
The presentation will feature data from preclinical studies of ORM-1153, a novel CD123-targeting DAC designed to deliver Orum’s proprietary GSPT1-degrading payload, SMol006, selectively into cancer cells to achieve targeted protein degradation and antitumor activity in acute myeloid leukemia (AML). The results support further investigation of ORM-1153 as a potential therapeutic option for AML and other CD123-positive hematologic malignancies, including those with TP53-mutant status.
Details of the ASH 2025 Presentation
Title: ORM-1153: A CD123-Targeting Degrader Antibody Conjugate with GSPT1-Degrading Payload Exhibits Potent Preclinical Antitumor Activity in Acute Myeloid Leukemia
Session: 604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Poster III
Session Type: Poster Presentation
Session Date and Time: December 8, 2025, from 6 pm to 8 pm ET
Location: Orange County Convention Center (OCCC), West Halls B3-B4
Abstract Number: 5051
About Orum’s TPD²® Approach
Orum’s unique Dual-Precision Targeted Protein Degradation (TPD²®) approach builds novel targeted protein degraders combined with the precise cell delivery mechanisms of antibodies to generate innovative, first-in-class, cell-selective TPDs for the treatment of cancer and other serious diseases. Orum has developed new targeted protein degrader payloads to specifically degrade an intracellular target protein within cancer cells via the E3 ubiquitin ligase pathway. Conjugated to antibodies, the payloads are designed to be delivered specifically to target cells and precisely degrade the intracellular target protein of interest.
About Orum Therapeutics
Orum Therapeutics is a public biotech pioneering the development of cell-specific, targeted protein degraders (TPD²®) with the precision of antibody targeting to develop the next generation of degrader antibody conjugates (DACs) for oncology and beyond. The company is advancing its GSPT1-directed TPD² programs and developing novel degrader payloads to expand the potential of targeted protein degradation. Orum's novel targeted protein degrader payloads are designed to selectively degrade key intracellular proteins, offering a highly targeted approach to treating difficult-to-treat diseases. Orum is located in Lexington, MA, US, and Daejeon, South Korea.
